Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Am Heart Assoc ; 5(10)2016 10 12.
Article in English | MEDLINE | ID: mdl-27733347

ABSTRACT

BACKGROUND: Diagnostic testing in the care of patients newly presenting with symptoms suggestive of coronary artery disease may influence risk factor management, independent of test type or test results. However, little is known about changes in medications and lifestyle after anatomical or functional testing. METHODS AND RESULTS: We examined what factors influenced preventive medical therapy and lifestyle practices at 60 days among 10 003 symptomatic patients (53% women; mean age 61 years) randomly assigned to anatomical testing with coronary computed tomographic angiography or functional testing (NCT01174550). We also assessed the association of preventive changes with major cardiovascular events. There were no differences in medications/lifestyle at baseline. At 60 days, relative to baseline, the computed tomographic angiography strategy was associated with a higher proportion of patients newly initiating aspirin (11.8% versus 7.8%), statins (12.7% versus 6.2%), and ß-blockers (8.1% versus 5.3%), compared to functional testing (P<0.0001 for each). No significant differences between computed tomographic angiography and functional testing strategies were observed for initiation of exercise, quitting smoking, or weight loss in overweight/obese patients, though overall prevalence of healthy eating was higher after computed tomographic angiography (P=0.002) while obese/overweight status was lower (P=0.040). Positive initial test results and revascularization demonstrated stronger associations with preventive medications and lifestyle than test type. Medication initiation was not associated with fewer cardiovascular events. CONCLUSIONS: Positive initial test results and revascularization are primary drivers of changes in preventive medical and lifestyle practices, with test type making secondary contributions. However, substantial opportunities exist to further reduce cardiovascular risk. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01174550.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Coronary Artery Disease/prevention & control , Diet, Healthy , Exercise , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Life Style , Platelet Aggregation Inhibitors/therapeutic use , Aged , Aspirin/therapeutic use , Computed Tomography Angiography , Coronary Artery Disease/diagnosis , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/therapy , Echocardiography, Stress , Exercise Test , Female , Follow-Up Studies , Humans , Male , Middle Aged , Obesity/epidemiology , Overweight/epidemiology , Patient Compliance , Randomized Controlled Trials as Topic , Smoking/epidemiology
2.
Int J Cardiovasc Imaging ; 28(5): 1161-71, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21863322

ABSTRACT

Liquefactive necrosis within a large spheroid zone of mitral annular calcification (LNMAC) is an atypical but increasingly recognized variant of mitral annular calcification (MAC). Proposed MRI, echo, and CT imaging criteria for diagnosis of this unusual disease entity are discussed along with a review of the prognosis, histopathology, and management implications. A comprehensive ECHO, CT, and MRI imaging approach to diagnostic differentiation from other cardiac masses, allowing characterization of the differing components of this unusual lesion is emphasized. Differentiation from surrounding myocardium, and demonstration of peripheral ring type hyperenhancement, or hyperintense signal in the wall of this lesion, seen with specific inversion recovery MRI sequences is presented as a major diagnostic criterion. The relationship of these MRI image findings to underlying pathology is also discussed. An illustrative case vignette is provided for clinical reference.


Subject(s)
Calcinosis/pathology , Heart Valve Diseases/diagnosis , Magnetic Resonance Imaging , Mitral Valve/pathology , Aged , Calcinosis/epidemiology , Calcinosis/prevention & control , Echocardiography , Heart Valve Diseases/epidemiology , Heart Valve Diseases/pathology , Heart Valve Diseases/therapy , Humans , Incidence , Male , Necrosis , Predictive Value of Tests , Prevalence , Prognosis , Tomography, X-Ray Computed
3.
Rev Cardiovasc Med ; 10(3): 152-63, 2009.
Article in English | MEDLINE | ID: mdl-19898292

ABSTRACT

Noninvasive visualization of the coronary arteries is the holy grail of cardiac imaging. Cardiac catheterization, the historic gold standard for coronary imaging, is invasive, costly, and often performed unnecessarily. Cardiac computed tomographic angiography (CCTA) is a widely available, cost-effective imaging modality that effectively images the coronary arteries. The most appropriate patient for a CCTA-guided approach to the evaluation of chest pain is the symptomatic patient at low to intermediate risk. Data are rapidly evolving to further validate the accuracy, prognostic ability, and cost-effectiveness of this technique. The current landscape of the American medical system and the rising cost of United States health care have led to skepticism concerning CCTA and its potential misuse. Technological misunderstanding and concern about excessive radiation exposure also threaten its growth. When used properly by appropriately trained physicians, CCTA adds significant value to the evaluation of chest pain and to the diagnosis of coronary artery disease.


Subject(s)
Coronary Angiography/methods , Coronary Artery Disease/diagnostic imaging , Radiographic Image Interpretation, Computer-Assisted , Tomography, X-Ray Computed , Angina Pectoris/diagnostic imaging , Angina Pectoris/etiology , Clinical Competence , Coronary Angiography/adverse effects , Coronary Artery Disease/complications , Humans , Imaging, Three-Dimensional , Patient Selection , Predictive Value of Tests , Prognosis , Radiation Dosage , Reproducibility of Results , Tomography, X-Ray Computed/adverse effects
4.
J Am Soc Echocardiogr ; 16(7): 764-9, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12835664

ABSTRACT

Diminished myocardial function can be seen in chronic coronary stenosis (CS) even in the presence of normal resting myocardial blood flow. We hypothesized that adenosine contributes to myocardial depression in this setting, predominantly through activation of the A(1) adenosine receptor. To test this hypothesis we used aminophylline, a nonselective adenosine receptor antagonist, and 8-cyclopentyl 1,3 dipropylxanthine, a selective A(1) adenosine receptor antagonist, in a canine model of chronic CS. Chronic CS was produced by placement of ameroid constrictors on the left anterior descending and left circumflex coronary arteries in 17 adult mongrel dogs, which resulted in severe left ventricular dysfunction 6 weeks later. Eight dogs without ameroid placement were used as controls (C). Closed-chest echocardiographic short-axis images at the low midpapillary level, hemodynamics, and radiolabeled microsphere-derived myocardial blood flow were obtained before and immediately after injection of either 5 mg/kg(-1) of aminophylline (7 left ventricular dysfunction and 4 C dogs) or 1 mg/kg(-1) of 8-cyclopentyl 1,3-dipropylxanthine (10 left ventricular dysfunction and 4 C dogs). Both 8-cyclopentyl 1,3-dipropylxanthine and aminophylline had no effect in C animals but resulted in a significant transient increase in regional percent wall thickening (P <.05) with a concomitant decrease in end-systolic wall stress (P <.05) in CS animals. There was no change in transmural myocardial blood flow or systemic hemodynamics to explain these results. Thus, adenosine plays a significant role in myocardial dysfunction in chronic ischemia by activation of the A(1) receptor. Aminophylline or a selective A(1) adenosine receptor antagonist can be used to detect viable myocardium and may be safer than dobutamine in severe chronic ischemic heart disease.


Subject(s)
Aminophylline/pharmacology , Coronary Stenosis/physiopathology , Myocardial Ischemia/physiopathology , Purinergic P1 Receptor Antagonists , Receptors, Purinergic P1/physiology , Xanthines/pharmacology , Animals , Dogs , Microspheres
5.
Circulation ; 106(1): 112-7, 2002 Jul 02.
Article in English | MEDLINE | ID: mdl-12093779

ABSTRACT

BACKGROUND: We hypothesized that increased myocardial oxygen demand resulting from hypotension and reflex tachycardia unmasking a reduced endocardial myocardial blood flow (MBF) reserve is the mechanism of dipyridamole-induced regional dysfunction in chronic coronary artery disease. METHODS AND RESULTS: Ameroid constrictors were placed around the proximal coronary arteries and their major branches in 15 dogs to create chronic coronary stenosis. Seven days later, radiolabeled microsphere-derived MBF and 2-dimensional echocardiography-derived percent wall thickening (%WT) were measured at rest and after 0.56 mg/kg dipyridamole. Dipyridamole caused an increase (mean, 21%) in the rate-pressure product secondary to reflex tachycardia resulting from mild systemic hypotension. %WT in myocardial segments with an endocardial MBF reserve (dipyridamole/resting MBF) of 1.5 to 2.5 (n=35) did not change after dipyridamole, whereas it decreased in segments with an endocardial MBF reserve of <1.5 (n=30) and increased in those with an endocardial MBF reserve of > or =2.5 (n=45) (P<0.05). Most (80%) segments with endocardial MBF reserve of <1.5 and 14% with an endocardial MBF reserve of 1.5 to 2.5 showed inducible dysfunction after dipyridamole, whereas none of the segments with an endocardial MBF reserve of > or =2.5 showed this finding. A sigmoid relation (y=-6.74/[1+exp (19.9. [x-1.84])]+1.35. x, r=0.93, P<0.0001) was noted between endocardial MBF reserve and Delta%WT. In contrast, neither the epicardial MBF reserve nor the endocardial/epicardial MBF ratio during hyperemia was associated with inducible regional dysfunction. CONCLUSIONS: Increased myocardial oxygen demand resulting from hypotension and reflex tachycardia unmasking a reduced endocardial MBF reserve is the primary mechanism of dipyridamole-induced regional dysfunction in chronic coronary artery disease.


Subject(s)
Coronary Stenosis/physiopathology , Dipyridamole/pharmacology , Vasodilator Agents/pharmacology , Animals , Blood Pressure/drug effects , Coronary Circulation/drug effects , Coronary Stenosis/diagnostic imaging , Dogs , Echocardiography, Stress , Endocardium/diagnostic imaging , Endocardium/physiopathology , Hemodynamics/drug effects , Pericardium/diagnostic imaging , Pericardium/physiopathology , Regional Blood Flow/drug effects , Tachycardia/chemically induced
6.
J Am Coll Cardiol ; 40(1): 167-74, 2002 Jul 03.
Article in English | MEDLINE | ID: mdl-12103272

ABSTRACT

OBJECTIVES: We hypothesized that, although the effects of dipyridamole and dobutamine on myocardial blood volume (MBV) and mean microbubble velocity (VEL) are different, the magnitude of perfusion deficit during both forms of stress is the same because both drugs unmask abnormal myocardial blood flow (MBF) reserve. BACKGROUND: Both dipyridamole and dobutamine are used clinically as pharmacologic stress agents to induce reversible perfusion defects in patients with chronic coronary artery disease (CAD), but the basis for doing so for dobutamine is not clear. METHODS: Eleven chronically instrumented closed-chest dogs with multivessel coronary stenosis were studied. Hemodynamics, radiolabeled microsphere-derived MBF, and myocardial contrast echocardiography (MCE)-derived myocardial perfusion were measured at rest, after dipyridamole infusion (0.56 mg x kg(-1)), and at peak dobutamine dose (either 30 or 40 microg x kg(-1) x min(-1)). Abnormal beds were defined as those demonstrating an MBF reserve <3 with dipyridamole. RESULTS: In the presence of either drug, MBV increased more in the normal bed than in the abnormal bed, but the increase was higher in both beds with dobutamine than with dipyridamole. The slope of the relationship between MBF reserve and MBV reserve was greater during dobutamine than dipyridamole (p < 0.05). The converse was true for VEL reserve (p < 0.05). Consequently, the relationship between the ratios of either variable, or the product of the two, between the abnormal bed and normal bed was similar for both drugs. CONCLUSIONS: Although the effects of dipyridamole and dobutamine on MBV and VEL are different, both are equally effective in detecting physiologically relevant coronary stenoses on MCE. Both can therefore be used interchangeably with myocardial perfusion imaging for the detection of CAD.


Subject(s)
Cardiotonic Agents , Coronary Circulation/physiology , Coronary Stenosis/physiopathology , Dipyridamole , Dobutamine , Vasodilator Agents , Animals , Blood Flow Velocity/drug effects , Cardiotonic Agents/pharmacology , Coronary Circulation/drug effects , Coronary Stenosis/diagnosis , Dipyridamole/pharmacology , Dobutamine/pharmacology , Dogs , Echocardiography , Microspheres , Vasodilator Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...